RxDoctor Payments Data

Melony Almany

Family · Greeneville, TNNPI 1255999330

Payments from drug & device makers

$4,416in general payments, 2019–2025

Across 242 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$810
  • Novartis$614
  • E.r. Squibb & Sons, L.L.C.$476
  • Irhythm Technologies, Inc.$366
  • Merck$323
  • Johnson & Johnson$246
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,402100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,416 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$31,274
Medicare patients
380
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$171,375
EntrestoSacubitril/Valsartan114$100,481
XareltoRivaroxaban57$62,694
NexlizetBempedoic Acid/Ezetimibe77$36,846
JardianceEmpagliflozin43$31,991
BrilintaTicagrelor21$17,533
Repatha SureclickEvolocumab26$17,399
NexletolBempedoic Acid31$14,118
Ranolazine ErRanolazine76$7,893
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$1,398
Nitroglycerin71$1,308
Metoprolol Succinate98$954
Metoprolol Tartrate124$736
Valsartan18$587
Amlodipine Besylate74$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$245$171,375183 claims
NovartisEntresto$614$100,481114 claims
Johnson & JohnsonXarelto$246$62,69457 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$32$50,964108 claims
Boehringer IngelheimJardiance$143$31,99143 claims
AstraZenecaBrilinta$193$17,53321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Greeneville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →